NCT00069030View on ClinicalTrials.gov

Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

December 31, 2006

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP

Trial Locations (7)

10003

NY Blood Ctr./Union Square CRS, New York

10032

HIV Prevention & Treatment CRS, New York

10456

NY Blood Ctr./Bronx CRS, The Bronx

21201

Project Brave HIV Vaccine CRS, Baltimore

02115

Brigham and Women's Hosp. CRS, Boston

02215

Fenway Community Health Clinical Research Site (FCHCRS), Boston

02906

Miriam Hospital's HVTU, Providence

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00069030 - Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults | Biotech Hunter | Biotech Hunter